May 18, 2018 09:45 AM EDTUpdated 10:07 AM
R&D

Ag­ile bris­tles af­ter FDA's third snub, promis­ing a fight for its con­tra­cep­tive

Brittany Meiling

Ag­ile Ther­a­peu­tics is start­ing to get testy af­ter suf­fer­ing yet an­oth­er snub from the FDA, an­nounc­ing this morn­ing that it sim­ply doesn’t agree with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times